Search results
Results from the WOW.Com Content Network
The Danish drugmaker said supply disruptions would start in mid-January, followed by discontinuation of the Levemir injection pen in April and of Levemir vials by the end of 2024. Novo has another ...
The Danish drugmaker said in November it would halt U.S. sales of Levemir by the end of 2024. ... Its market value has risen by $380 billion since it launched anti-obesity injection Wegovy three ...
Levemir's U.S. sales were 1.27 billion Danish crowns ($185.6 million) in 2023. Sales of Novo's other long-acting insulin Tresiba were 1.33 billion crowns last year. ($1 = 0.9172 euros)
Insulin detemir, sold under the brand name Levemir among others, is a long-acting modified form of medical insulin used to treat both type 1 and type 2 diabetes. [6] It is used by injection under the skin . [ 6 ]
Drugs or medicines may be withdrawn from commercial markets because of risks to patients, but also because of commercial reasons (e.g. lack of demand and relatively high production costs).
In many people, both a rapid- or short-acting insulin product as well as an intermediate- or long-acting product are used to decrease the amount of injections per day. In some, insulin injections may be combined with other injection therapy such as GLP-1 receptor agonists. Cleansing of the injection site and injection technique are required to ...
Recent research (Nixon & Vendelø, 2016) shows that General Practitioners (GPs) who actively consider discontinuation, are reluctant to do so, as they experience that the safest decision is to continue prescriptions, rather than discontinue them. In part this is due to the ambiguity about the appropriateness of discontinuing medication.
(Reuters) -Drugmaker Indivior Plc slashed its 2024 profit forecast while signaling a slowdown in sales of its top-selling opioid addiction treatment, and said it would discontinue sales of its ...